RNA vs SRPT

Avidity Biosciences (RNA) continues to demonstrate strong 10x growth potential, sustained by its proprietary Antibody Oligonucleotide Conjugate (AOC) platform. The lead asset, AOC 1001 for Myotonic Dystrophy Type 1 (DM1), remains critically important, with the path to potential regulatory filing in late 2026/early 2027 still intact. This timeline, coupled with ongoing clinical progress for AOC 102...

Sarepta's 10x growth potential remains tightly linked to the successful, rapid commercialization of Elevidys, its gene therapy for Duchenne Muscular Dystrophy (DMD). While the expanded traditional approval in late 2023 significantly de-risked the regulatory path, market sentiment, as reflected in the market cap, has stabilized slightly from $1.94B to $1.97B since our last analysis 17 days ago, hal...